HCM
HUTCHMED (China) Ltd
$10.96
+2.62%
$1.9B
No data for this timeframe.
Vol
Market Cap$1.9B
Cap SizeSmall Cap
Inst. Holders25 funds
Inst. Value$51.5M
Inst. Activity1 buys / 4 sells
Reddit Sentiment50° Neutral
SEC Reports1
Press Releases5
Recent Activity
Jun 12, 2026
SEC
HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at EHA 2026, showing a 66% durable response rate vs
6-K — Impact 7/10
May 20, 2026
Insider
Chiu Lorenso acquired 5,176 shares
Deputy Chief Financial Officer
May 20, 2026
Insider
Chiu Lorenso acquired 8,863 shares
Deputy Chief Financial Officer
May 20, 2026
Insider
Su Wei-guo acquired 132,864 shares
CEO and CSO
Inst.
SCHRODER INVESTMENT MANAGEMENT GROUP — TRIM
1,477,494 shares ($22.1M)
Inst.
BANK OF AMERICA CORP — TRIM
12,489 shares ($186.8K)
Jun 12, 2026
Press
HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs
Impact 7/10
Jun 12, 2026
fda
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
<p align="center"><em>— Sovleplenib demonstrated rapid and durable hemoglobin response with favorabl
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$22.83 (Mar 2026)
Current $10.96
Low $13.60
Median $20.64
High $40.40
14 analysts
$13.60
$40.40
Analyst Ratings
10Strong Buy
13Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 10, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $0.38 | $0.09 — $0.58 | -85% YoY | 5 |
| Next FY | $0.49 ▼ -5.0% | $0.13 — $0.93 | 28% YoY | 5 |
Latest Reports
BULLISH
6-K
7/10
HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at EHA 2026, showing a 66% durable response rate vs
Jun 12, 2026
BULLISH
Press
7/10
HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs
Jun 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | $22.1M | TRIM |
| Allianz Asset Management GmbH | $12.5M | — |
| STATE STREET CORP | $4.6M | — |
| M&G Plc | $3.8M | ADD |
| Amundi | $3.5M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Chiu Lorenso | J | $0.00 |
| May 20, 2026 | Chiu Lorenso | J | $0.00 |
| May 20, 2026 | Su Wei-guo | J | $0.00 |
| May 20, 2026 | Su Wei-guo | J | $0.00 |
| May 20, 2026 | Nixon Charles | J | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
25 institutional holders with $51.5M total value (3,442,660 shares) as of 2026-Q1. Top holders: SCHRODER, Allianz, STATE. Net selling activity: 4 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | SCHRODER INVESTMENT MANAGEMENT GROUP | 1,477,494 | $22.1M | 42.9% | TRIM -35.2% |
| 2 | Allianz Asset Management GmbH | 837,475 | $12.5M | 24.3% | — |
| 3 | STATE STREET CORP | 304,829 | $4.6M | 8.9% | — |
| 4 | M&G Plc | 255,468 | $3.8M | 7.4% | ADD +26.7% |
| 5 | Amundi | 232,246 | $3.5M | 6.7% | ADD +41.9% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 132,062 | $2.0M | 3.8% | TRIM -28.3% |
| 7 | DIMENSIONAL FUND ADVISORS LP | 55,969 | $837.3K | 1.6% | DOUBLED +157.7% |
| 8 | CITADEL ADVISORS LLC | 30,514 | $456.5K | 0.9% | TRIM -68.2% |
| 9 | Vanguard Personalized Indexing Management, LLC | 20,425 | $305.6K | 0.6% | — |
| 10 | Vident Advisory, LLC | 17,726 | $265.2K | 0.5% | TRIM -42.3% |
| 11 | Orion Porfolio Solutions, LLC | 15,961 | $238.8K | 0.5% | — |
| 12 | AMERIPRISE FINANCIAL INC | 14,962 | $223.8K | 0.4% | — |
| 13 | BANK OF AMERICA CORP /DE/ | 12,489 | $186.8K | 0.4% | TRIM -41.0% |
| 14 | MORGAN STANLEY | 11,350 | $169.8K | 0.3% | TRIM -72.6% |
| 15 | Mariner, LLC | 10,925 | $163.3K | 0.3% | TRIM -25.1% |
| 16 | RHUMBLINE ADVISERS | 4,096 | $61.3K | 0.1% | ADD +46.2% |
| 17 | FMR LLC | 3,531 | $52.8K | 0.1% | — |
| 18 | ROYAL BANK OF CANADA | 2,660 | $40.0K | 0.1% | TRIM -62.4% |
| 19 | Rockefeller Capital Management L.P. | 963 | $14.4K | 0.0% | — |
| 20 | BlackRock, Inc. | 791 | $11.8K | 0.0% | NEAR_EXIT -98.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | TRIM | 2,279,541 | 1,477,494 | -35.2% | $22.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 21,183 | 12,489 | -41.0% | $186.8K | 2026-Q1 |
| BlackRock, Inc. | NEAR_EXIT | 39,679 | 791 | -98.0% | $11.8K | 2026-Q1 |
| ASSETMARK, INC | DOUBLED | 38 | 187 | +392.1% | $2.8K | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 28 | 2 | -92.9% | $30.00 | 2026-Q1 |
| M&G Plc | ADD | 204,432 | 259,033 | +26.7% | $3.4M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 21,721 | 55,969 | +157.7% | $746.1K | 2025-Q4 |
| BlackRock, Inc. | ADD | 23,220 | 39,679 | +70.9% | $528.9K | 2025-Q4 |
| Mariner, LLC | TRIM | 14,346 | 10,748 | -25.1% | $143.2K | 2025-Q4 |
| RHUMBLINE ADVISERS | ADD | 2,757 | 4,032 | +46.2% | $53.7K | 2025-Q4 |
| ASSETMARK, INC | DOUBLED | 15 | 38 | +153.3% | $507.00 | 2025-Q4 |
| Amundi | ADD | 157,432 | 223,330 | +41.9% | $3.6M | 2025-Q3 |
| UBS Group AG | DOUBLED | 64,386 | 137,000 | +112.8% | $2.2M | 2025-Q3 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 16,183 | 21,721 | +34.2% | $342.1K | 2025-Q3 |
| MARSHALL WACE, LLP | TRIM | 19,882 | 14,897 | -25.1% | $234.6K | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 37,411 | 11,913 | -68.2% | $187.6K | 2025-Q3 |
| UBS Group AG | TRIM | 216,565 | 64,386 | -70.3% | $969.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 47,262 | 27,641 | -41.5% | $416.0K | 2025-Q2 |
| Vident Advisory, LLC | TRIM | 19,728 | 11,374 | -42.3% | $171.2K | 2025-Q2 |
| Russell Investments Group, Ltd. | TRIM | 107 | 42 | -60.7% | $632.00 | 2025-Q2 |
| BARCLAYS PLC | TRIM | 6,509 | 2,442 | -62.5% | $37.00 | 2025-Q2 |
| UBS Group AG | TRIM | 377,728 | 216,565 | -42.7% | $3.3M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 188,539 | 135,200 | -28.3% | $2.0M | 2025-Q1 |
| BlackRock, Inc. | DOUBLED | 15,601 | 73,308 | +369.9% | $1.1M | 2025-Q1 |
| Vident Advisory, LLC | ADD | 11,064 | 19,728 | +78.3% | $296.7K | 2025-Q1 |
4 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Chiu Lorenso | Deputy Chief Financial Officer | J | 5,176 | — | — |
| May 20, 2026 | Chiu Lorenso | Deputy Chief Financial Officer | J | 8,863 | — | — |
| May 20, 2026 | Su Wei-guo | CEO and CSO | J | 132,864 | — | — |
| May 20, 2026 | Su Wei-guo | CEO and CSO | J | 75,140 | — | — |
| May 20, 2026 | Nixon Charles George Rupert | Group General Counsel | J | 7,445 | — | — |
| May 20, 2026 | Nixon Charles George Rupert | Group General Counsel | J | 7,644 | — | — |
| May 20, 2026 | Cheng Chig Fung | Acting CEO and CFO | J | 30,157 | — | — |
| May 20, 2026 | Cheng Chig Fung | Acting CEO and CFO | J | 26,307 | — | — |
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
BULLISH
7/10
HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% dura
Jun 12, 2026
MIXED
6/10
HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibo
Apr 9, 2026
BULLISH
7/10
HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibit
Mar 23, 2026
MIXED
6/10
HUTCHMED reported mixed financial results for 2025, with a significant $457 million net income drive
Mar 5, 2026
NEUTRAL
5/10
HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Ther
Mar 4, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 88% buy across 26 analysts — 10 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$22.83 mean target (Mar 2026)
$13.60 Low
$40.40 High
| Metric | Value |
|---|---|
| Current Price | $10.96 |
| Target Low | $13.60 |
| Target Mean | $22.83 |
| Target Median | $20.64 |
| Target High | $40.40 |
| # Analysts | 14 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.38 | $0.09 | $0.58 | -85.3% | +0.0% | 0↑ 2↓ | $0.6B | 16.4% | 5 |
| Next FY 2027-12-31 |
$0.49 | $0.13 | $0.93 | 28.5% | -5.0% | 0↑ 1↓ | $0.7B | 14.5% | 5 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 10, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 13 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Apr 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Mar 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| Feb 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| Jan 1, 2026 | 9 | 15 | 2 | 1 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 28, 2025 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Alternative Nuclear Plays To OKLO/SMR
▲ 13
💬 15
⚡ 0.0
Jun 12, 2026
fda
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
<p align="center"><em>— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —</em></p>
May 22, 2026
routine
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
<p align="justify">HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www.globenewswire.
May 21, 2026
other
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study <pre>Reduced risk of disease p
Apr 9, 2026
fda
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 23, 2026
fda
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 9, 2026
other
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 6, 2026
other
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
<p align="justify">HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“<a href="https://www
Mar 5, 2026
earnings
HUTCHMED Reports 2025 Full Year Results and Business Updates
<p align="center"><em>— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth —</em></p>
Mar 4, 2026
fda
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
<p align="center"><em>— Second clinical candidate from HUTCHMED’s next-generation ATTC platform —</em></p>